Dr. Reginald Seeto Appointed as CEO and President, to Lead Scipher Medicine's Next Phase of Growth

2024-05-09

高管变更

WALTHAM, Mass.--(BUSINESS WIRE)-- Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President. Scipher developed SpectraTM, a proprietary AI platform that has been used to build both an autoimmune diagnostic and an emerging biopharmaceutical business. In the diagnostics business, PrismRA® was recently approved by MolDx for therapy selection in rheumatoid arthritis patients, and in the biopharmaceutical business, recent deals have focused on generating novel target discovery and data insights for partners. Dr. Seeto is a seasoned CEO and Board Member who brings more than two decades of leadership experience across both diagnostic and therapeutic companies. "Reg has an established leadership track record in building both products and companies by setting bold strategies that can be delivered through high performing teams. His deep understanding of the diagnostic and therapeutic industry makes him the right person to lead Scipher going forward," said Samir Kaul, Managing Director at Khosla Ventures and a member of the Scipher Board of Directors. Dr. Seeto was most recently the CEO and President of CareDx ("CDNA"), a company focused on the transplant patient. Under Dr. Seeto's leadership, CareDx was recognized as one of the fastest-growing companies in North America by Deloitte's Technology Fast 500 driven by its innovative transplant diagnostic business. During his tenure, he grew business lines across this patient journey, including building a denovo patient and digital solution business through acquisitions and partnerships. Prior to this, he was the Chief Operating Officer at Ardelyx ("ARDX"), and EVP of Corporate Development and Strategy at Medimmune, the biologics division of AstraZeneca (“AZN”). Earlier in his career, he held both US and global leadership positions at Boehringer Ingelheim and Organon, respectively. He launched his career as a physician-scientist with both clinical and research roles and worked as a strategy consultant at McKinsey & Company. "I am thrilled to be joining Scipher, where we can grow the business because of the ongoing unmet need in treating patients with autoimmune disease and with the significant opportunity to partner with biopharmaceutical companies." said Dr Seeto, “Importantly, one of the key attractions in joining was the ability to work with the world-class caliber board at Scipher." Recently, Scipher has also appointed Glenn Muir as Independent Director to its Board and as Chair of the Audit Committee. Muir brings over 30 years of experience to the role, with a distinguished career in the life sciences industry. Most notably, he spent 26 years at Hologic, Inc., a leading multinational medical device and diagnostics company. At Hologic, Muir served as Chief Financial Officer (CFO) and Executive Vice President, playing a key role in the company's remarkable growth. He helped steer Hologic's evolution from a venture-backed startup to a publicly traded, diversified organization with over 5,000 employees and $2.5 billion in revenue. Muir's impressive track record extends beyond Hologic. He currently serves on the boards of directors for several publicly traded companies in the life sciences sector, including Repligen Corporation, G1 Therapeutics, Inc., and Neuronetics, Inc. He has also held board positions at ReWalk Robotics Ltd. and RainDance Technologies, Inc. "I am honored to be appointed Chair of the Audit Committee at Scipher," said Mr. Muir. "Scipher's mission to revolutionize precision immunology through its innovative data platform is truly groundbreaking. I look forward to leveraging my experience to contribute to the company's continued success." "We are thrilled to welcome Glenn to the Audit Committee Chair role," said Tim Anderson, Managing Director at Blue Own Capital and a member of the Scipher Board of Directors "his extensive financial expertise and proven leadership in the life sciences industry will be invaluable to Scipher as we pursue our ambitious growth plans. His addition to Scipher underscores the company’s commitment to strong corporate governance and financial oversight." Seeto and Muir’s appointment mark a significant step forward for Scipher as the company positions itself for continued growth within the field of precision immunology. *MBBS is equivalent to a MD in the United States About Scipher Medicine Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. Using Spectra™, a proprietary network medicine platform, Scipher commercializes tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. Scipher partners with leading payers, healthcare providers, and pharmaceutical companies to bring solutions to patients across diseases. To learn more about Scipher visit sciphermedicine.com and follow Scipher Medicine on Facebook, X, and LinkedIn. About PrismRA® PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world’s largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to inform therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit PrismRA.com.